帕金森病临床治疗药物的制剂改良策略  

Preparation modification strategies for clinical treatment drugs of Parkinson's disease

作　　者：何梦娇 肖伊芳 孔祥安妮 刘智昊 王孝广 冯浩 涂家生[1] 陈芊 孙春萌[1] HE Meng-jiao;XIAO Yi-fang;KONG Xiang-an-ni;LIU Zhi-hao;WANG Xiao-guang;FENG Hao;TU Jia-sheng;CHEN Qian;SUN Chun-meng(NMPA Key Laboratory for Research and Evaluation of Pharmaceutical Preparations and Excipients,School of Pharmacy,China Pharmaceutical University,Nanjing 210009,China;Nanjing Lanming Biomedical Technology Co.,Ltd.,Nanjing 210028,China)

机构地区：[1]国家药品监督管理局药物制剂及辅料研究与评价重点实验室,中国药科大学药学院,江苏南京210009 [2]南京兰铭生物医疗科技有限公司,江苏南京210028

出　　处：《药学学报》2024年第3期574-580,共7页Acta Pharmaceutica Sinica

摘　　要：帕金森病(Parkinson's disease,PD)是一种慢性神经退行性疾病,目前主要以左旋多巴等药物进行多巴胺补充治疗,但左旋多巴在胃肠道吸收不稳定且半衰期短,长期服用会导致剂末现象、异动症、开关效应等症状的发生,因此需要研发新型制剂以提高药效、降低不良反应或提高患者用药依从性,基于以上临床需求,本文通过案例分析介绍了用于帕金森病治疗的制剂改良策略,以期为相关制剂的研发提供思路。Parkinson's disease(PD)is a chronic neurodegenerative disease.At present,levodopa and other drugs are mainly used for dopamine supplementation therapy.However,the absorption of levodopa in the gastrointestinal tract is unstable and its half-life is short,and long-term use of levodopa will lead to the end-of-dose deterioration,dyskinesia,the"ON-OFF"phenomenon and other symptoms.Therefore,new preparations need to be developed to improve drug efficacy,reduce side effects or improve compliance of patients.Based on the above clinical needs,this review briefly introduced the preparation modification strategies for the treatment of PD through case analysis,in order to provide references for the research and development of related preparations.

关 键 词：帕金森病 左旋多巴 卡比多巴 多巴胺受体激动剂 剂型 

分 类 号：R943[医药卫生—药剂学]